RxDoctor Payments Data

Roger Dehoyos, APRN

Acute Care · Crystal City, TXNPI 1396214706

Payments from drug & device makers

$2,707in general payments, 2019–2025

Across 135 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$514
  • Johnson & Johnson$406
  • Novartis$356
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$214
  • Abbott$196
  • E.r. Squibb & Sons, L.L.C.$189
  • plus $832 from 9 others

What the payments were for

  • Food & beverage$2,69399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,707 in reported general payments places this provider in the 85th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$14,888
Medicare patients
85
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$83,641
EntrestoSacubitril/Valsartan75$67,747
XareltoRivaroxaban49$42,911
FarxigaDapagliflozin Propanediol11$9,427
VerquvoVericiguat12$7,172
Metoprolol Succinate195$1,933
Nebivolol Hcl13$900
Ranolazine ErRanolazine14$848
Ezetimibe19$709
Diltiazem 24hr ErDiltiazem Hcl25$694
Atorvastatin Calcium81$513
Potassium Chloride29$471
Carvedilol88$461
Rosuvastatin Calcium19$416
ClopidogrelClopidogrel Bisulfate49$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$154$83,64189 claims
NovartisEntresto$356$67,74775 claims
Johnson & JohnsonXarelto$406$42,91149 claims
AstraZenecaFarxiga$91$9,42711 claims
MerckVerquvo$514$7,17212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,323 acute care providers in Texas.

Other acute care in Crystal City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →